Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22895984 | 0.79 | CAPN1 (0.65) | CAPN1CTSS | |
| SCHEMBL20028593 | 0.77 | CAPN1 (0.62) | CAPN1CTSS | |
| SCHEMBL4990132 | 0.76 | CAPN1 (0.60) | CAPN1 | |
| SCHEMBL8443478 | 0.76 | CTSL (0.62) | CAPN1CTSS | |
| SCHEMBL24010407 | 0.75 | CAPN1 (0.60) | CAPN1 | |
| SCHEMBL28020981 | 0.75 | CAPN1 (0.59) | CAPN1 | |
| SCHEMBL23355176 | 0.73 | ITGB2 (0.59) | CAPN1 | |
| SCHEMBL23355175 | 0.73 | ITGB2 (0.59) | CAPN1 | |
| SCHEMBL24008817 | 0.72 | HPGDS (0.65) | CAPN1CTSS | |
| SCHEMBL20028594 | 0.72 | CAPN1 (0.56) | CAPN1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9527811-B2 | Carboxamide compounds and their use as calpain inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-12-27 | — | — | US | claimed |
| US-9018206-B2 | Carboxamide compounds and their use as calpain inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-04-28 | — | — | US | claimed |
| US-20150099786-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-04-09 | — | — | US | claimed |
| US-20130150367-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT LABORATORIES (US) | 2013-06-13 | — | — | US | claimed |
| US-20110086879-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2011-04-14 | — | — | US | claimed |
| US-20100286146-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2010-11-11 | — | — | US | claimed |
| EP-2427429-B1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBVIE DEUTSCHLAND (DE) | 2017-02-15 | — | — | EP | disclosed |
| US-9527811-B2 | Carboxamide compounds and their use as calpain inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-12-27 | — | — | US | disclosed |
| US-9018206-B2 | Carboxamide compounds and their use as calpain inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-04-28 | — | — | US | disclosed |
| US-20150099786-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-04-09 | — | — | US | disclosed |
| US-20130150367-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT LABORATORIES (US) | 2013-06-13 | — | — | US | disclosed |
| US-8283363-B2 | Carboxamide compounds and their use as calpain inhibitors | ABBOTT LABORATORIES (US) | 2012-10-09 | — | — | US | disclosed |
| US-8236798-B2 | Carboxamide compounds and their use as calpain inhibitors | ABBOTT GMBH & CO. KG (DE) | 2012-08-07 | — | — | US | disclosed |
| EP-2427429-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | Abbott GmbH & Co. KG (DE) | 2012-03-14 | — | — | EP | disclosed |
| US-20110086879-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2011-04-14 | — | — | US | disclosed |
| WO-2010128102-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286146-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286146-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | CAPN1, CAPN2, CAPNS1 | CAPN1 1/4885CTSS 46/4885 |
| US-20130150367-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | CAPN1, CAPN2, CAPNS1 | CAPN1 1/4885CTSS 46/4885 |
| US-20110086879-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | CAPN1, CAPN2, CAPNS1 | CAPN1 1/4885CTSS 46/4885 |
| US-20150099786-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | CAPN1, CAPN2, CAPNS1 | CAPN1 1/4885CTSS 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.